MediciNova Q2 net loss $2.3 mln

By Admin
MediciNova Inc said it has reported a net loss of $2.3 million or $0.14 per share in second quarter ended June 30, 2012. The biopharmaceutical company...

MediciNova Inc said it has reported a net loss of $2.3 million or $0.14 per share in second quarter ended June 30, 2012. The biopharmaceutical company had reported a net loss of $4.7 million or $0.31 a share in the corresponding period last year.

The research and development service revenue pertaining to the Kissei services agreement was $0.5 million.

In the second quarter, MediciNova’s R&D expenses stood at $1.5 million compared to $2.0 million posted in the same quarter last year. The decline in the R&D expenses was on account of a decrease in the spending on the prioritized asset MN-221 for treating acute exacerbations of asthma and COPD. Another reason for the plunge in R&D expenses is the lower stock based compensation expense in the most recent quarter.

For the quarter ended June 30, 2012, the general and administrative expenses fell by $1.3 million due to the decrease in the stock-based compensation expense, partially offset by increase in compensation expense pertaining to the bonus of employees.

The company had $7.3 million in cash and cash equivalents as of June 30, 2012, as against $15.1 million of cash and cash equivalents at December 31, 2011.

MediciNova is a publicly traded biopharmaceutical company founded on acquisition of developing novel, small-molecule therapeutics for treating diseases with unmet needs with a commercial focus on the U.S. market.

Share

Featured Articles

Hyfe AI uses acoustic AI in its digital cough monitoring

Hyfe uses acoustic AI in its digital cough monitoring. Dr. Joe Brew, Co-Founder & CEO of Hyfe AI, tells us more about coughing technology post-COVID-19

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Digital Healthcare

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma